AE Management Could Affect Compliance in Breast Cancer Treatment
It is important that nurses talk with their patients about what kind of adverse events to expect while being treated for HER2-positive breast cancer.
Related Articles
Olanzapine/Triplet Cuts Chemo-Induced Nausea, Vomiting in Breast Cancer
Those who took dexamethasone reported higher levels of satisfaction than patients on placebo.
Consistent Monitoring Is Key Post Endocrine Therapy in HR+, HER2– mBC
For patients who have progressed on endocrine therapy, consistent monitoring of blood counts and biomarker testing informs treatment sequencing.
SUD, Remote Monitoring Appears Feasible for Outpatient BiTE in MM
Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even in cases of CRS.
Irpagratinib/Atezolizumab Active in FGF19+ Advanced HCC
Irpagratinib plus atezolizumab showed durable responses and manageable safety in advanced HCC with FGF19 overexpression, regardless of prior ICI exposure.
Temferon Shows Early Signs of 3-Year Survival, Disease Control in GBM
Treatment with Temferon led to prolonged survival and possible disease control in 2 patients with newly diagnosed glioblastoma multiforme.
FDA Approves SIR-Spheres Y-90 Resin Microspheres for Unresectable HCC
The selective internal radiation therapy SIR-Spheres has been approved by the FDA for use in patients with unresectable hepatocellular carcinoma.
Atebimetinib Combo Shows Survival Signal in First-Line Pancreatic Cancer
The novel MEK inhibitor atebimetinib plus chemo showed early signs of survival benefit in first-line treatment of patients with pancreatic cancer.
Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment
Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.
BCI, Patient Preference Guide Nurses in 5-Year Endocrine Counseling
The BCI and patient goals help oncology nurses counsel patients on endocrine therapy use after 5 years, per Michelle Kirschner RN, MSN, ACNP, APRN-BC.
Anemia Protocol Does Not Reduce Ruxolitinib Efficacy in Myelofibrosis
Adding danazol or erythropoiesis-stimulating agents for anemia management to a ruxolitinib regimen for myelofibrosis does not decrease treatment efficacy.